Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy

Discovery and development of ANV419, an IL-2/anti-IL-2 antibody fusion protein with potent CD8+ T and natural killer cell-stimulating capacity for cancer immunotherapy

Novel engineered IL-2 agonists strive to increase the therapeutic window of aldesleukin (human IL-2) by increasing selectivity toward effector over regulatory T cells and reducing dose-limiting toxicities. Here we describe ANV419, an IL-2/anti-IL2 antibody fusion protein designed for selective IL-2...

Full description

Saved in:
Bibliographic Details
Main Authors: Patrizia Murer, Barbara Brannetti, Jean-Michel Rondeau, Laetitia Petersen, Nicole Egli, Simone Popp, Catherine Regnier, Kirsten Richter, Andreas Katopodis, Christoph Huber
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:mAbs
Subjects:
ANV419
cancer immunotherapy
effector T cells
IL-2Rβγ agonist
immunocytokine
immunotherapy
Online Access:https://www.tandfonline.com/doi/10.1080/19420862.2024.2381891
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items